false 0001377121 0001377121 2024-09-17 2024-09-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 17, 2024

 

 

 

PROTAGONIST THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-37852   98-0505495
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

  

Protagonist Therapeutics, Inc. 

7707 Gateway Blvd., Suite 140

Newark, California 94560-1160

(Address of principal executive offices, including zip code)

 

(510) 474-0170

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which
registered
Common Stock, par value $0.00001   PTGX   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On September 17, 2024, Daniel N. Swisher Jr., a member of the Board of Directors (the “Board”) of Protagonist Therapeutics, Inc. (the “Company”) and a member of the Audit Committee of the Board, resigned from the Board, effective September 17, 2024.  Mr. Swisher did not advise the Company of any disagreement with the Company on any matter relating to its operations, policies or practices.  Mr. Swisher will continue to serve as an advisor to the Company pursuant to an advisory agreement.

 

Effective September 19, 2024, Sarah A. O’Dowd, a member of the Board, was appointed to the Audit Committee of the Board, and the size of the Company's Board of Directors was reduced from seven to six.

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Protagonist Therapeutics, Inc.
Dated: September 19, 2024  
  By: /s/ Asif Ali
  Asif Ali
    Chief Financial Officer

 

 

v3.24.3
Cover
Sep. 17, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 17, 2024
Entity File Number 001-37852
Entity Registrant Name PROTAGONIST THERAPEUTICS, INC.
Entity Central Index Key 0001377121
Entity Tax Identification Number 98-0505495
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 7707 Gateway Blvd.
Entity Address, Address Line Two Suite 140
Entity Address, City or Town Newark
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94560-1160
City Area Code 510
Local Phone Number 474-0170
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.00001
Trading Symbol PTGX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Grafico Azioni Protagonist Therapeutics (NASDAQ:PTGX)
Storico
Da Ott 2024 a Nov 2024 Clicca qui per i Grafici di Protagonist Therapeutics
Grafico Azioni Protagonist Therapeutics (NASDAQ:PTGX)
Storico
Da Nov 2023 a Nov 2024 Clicca qui per i Grafici di Protagonist Therapeutics